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Abstract
Background: Surgical site infections (SSIs) are among the most common healthcare-associated infections. Under-
nutrition is an important risk factor for SSIs and can lead to delayed wound healing and longer hospital stays. Oral
nutritional supplements are prescribed to reduce the risk of infection and improve health status, but data from
randomised controlled trials (RCTs) have shown mixed results. Thus, the objective of our planned systematic review
is to evaluate oral nutritional supplements on preventing SSIs in adult surgical patients
Methods: RCTs conducted in adult surgical patients who receive oral nutritional support will be included. The
primary outcome will be the incidence of SSIs (within 30 days of surgery or within 90 days for joint replacement
surgery). Secondary outcomes will be changes in nutritional status, mortality, health-related quality of life and costs.
Literature searches will be conducted in several electronic databases (from inception onwards): MEDLINE, Embase,
CINAHL and The Cochrane Central Register of Controlled Trials (CENTRAL). Grey literature will be identified through
searching clinical trial registers and dissertation databases. Two reviewers will independently screen all citations, full-
text articles and abstract data. The study methodological quality (or bias) will be appraised using the Cochrane risk
of bias tool. If feasible, we will conduct random effects meta-analysis where appropriate.
Discussion: This systematic review will evaluate the evidence for pre- and post-surgical intervention with oral
nutritional supplements in adults. Findings from this planned review may inform subsequent nutritional
interventions for hospitalised patients who undergo surgery.
Systematic review registration: PROSPERO CRD42020140954
Keywords: Surgical site infection, Malnutrition, Nutrition, Surgery
Background
Surgical site infections (SSIs) are defined by the Centers
for Disease Control and Prevention (CDC) as infections
that occur after surgery in the part of the body or the in-
cision where the surgery took place. SSIs range from
simple wound infections involving the skin and subcuta-
neous tissues (classified as superficial incisional), to deep
soft-tissue infections involving fascia and muscle (classi-
fied as deep incisional), or infections of the space or
organ manipulated during the surgical procedure (classi-
fied as organ/space) [1]. SSIs are among the most com-
mon healthcare-associated infections, as the World
Health Organisation (WHO) estimates a pooled global
SSI incidence rate of 11.2% [2]. However, variations of
SSI incidence are marked. In one North American study
of over 750,000 surgical patients, 1% of procedures re-
sulted in an SSI, with similar incidence rates found in
other developed health systems [3, 4]. In a study of 75,
695 patients in hospitals in the United Kingdom (UK)
over a 4-month period, 8% of patients suffered a
healthcare-associated infection, with SSIs making up
15% of these infections [5]. Depending on whether the
surgery is classified as clean, clean/contaminated,
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contaminated or dirty, SSIs can also occur at different
rates [6]. Nonetheless, the prevalence of SSIs may be
under-estimated as most present within 30 days follow-
ing a surgical procedure; a proportion of which is likely
to develop outside of hospital [7, 8].
SSIs result in delayed wound healing, increased hos-
pital stays, increased use of antibiotics, unnecessary pain
and, in extreme cases, death of the patient [9]. SSIs re-
sult in delayed wound healing, increased hospital stays,
increased use of antibiotics, unnecessary pain, death of
the patient in extreme cases, as well as increased health
resource use and expenditure depending of the location,
depth and severity of the infection [10, 11]. Factors that
contribute to the development of SSI include the pa-
tient’s health status, the type of surgery conducted and
the physical environment where surgical care is provided
[12]. Surgical risk factors include emergency surgery or
surgeries involving major blood loss, surgery involving
contaminated or dirty wounds and prolonged surgery
[9]. Patient-level factors include a preoperative American
Society of Anesthesiology (ASA) score of III or IV
[13, 14], high body mass index (BMI) > 35, malnutri-
tion, advanced age and the pre-existence of immune-
compromising conditions or diseases such as diabetes and
cancer and malnutrition from inadequate nutritional
intake [15, 16]. Hospitalisation is also associated with a
deterioration of nutritional intake in admitted elective sur-
gical patients leading to under-nutrition [17].
Malnutrition can cause poor clinical outcomes from
surgery through disruption to physiological and psycho-
logical health [18]. Although no universally accepted
definition is clear, malnutrition can be broadly described
as any imbalance in an individual’s nutritional status
which affects body composition and/or function: such
imbalance might relate to overnutrition through exces-
sive nutritional intake or under-nutrition caused by
insufficient nutritional intake or malabsorption [19–21].
Most screening tools typically only distinguish under-
nourished patients rather than stratifying nutritional sta-
tus according to whether they are of normal weight or
obese/overweight [22, 23]. Consequently, the stratifica-
tion of risk among malnourished, normal weight and
obese patients is poorly understood. Moreover, compli-
ance with routine screening of nutritional status is
inconsistently performed in hospitals, even in countries
such as the UK and the United States of America (USA)
where it is mandatory on admission [24, 25]. Although
the quality of research varies, reported under-nutrition
ranges from 30 to 55% in hospitalised patients in studies
conducted across a range of countries [26–30].
Oral nutritional supplements contain either macronutri-
ents (proteins, fats, carbohydrates and amino acids) and/or
micronutrients (vitamins and minerals) to supplement the
oral diet. Some ingredients in oral nutritional supplements
such as proteins, arginine, glutamine, omega-3 fatty acids,
vitamins and trace minerals may improve immune function
and wound healing [31]. Nutrients such as arginine and
glutamine are typically referred to as immunonutrition.
Oral nutritional supplements containing macronutrients,
micronutrients or a mixture of both are usually prescribed
if under-nutrition is diagnosed or the patient is assessed as
being nutritionally at-risk, and an improvement in the
nutritional status is desired or required [20, 32]. To achieve
improvements in nutritional status, oral nutritional supple-
ments are usually prescribed for at least 7 days before sur-
gery [33] and up to 4 weeks postoperatively [34]; however,
protocols vary. Typically, oral nutritional supplements are
taken as liquids up to three times a day with an intake of
about 250–600 kcal/daily usually in addition to daily dietary
intake [18].
Under-nutrition results from a shortfall between nutri-
tion intake and nutrient requirements leading to tissue
loss and changes to normal physiological function [35].
Surgical patients may be undernourished on admission
to hospitals [36]. Surgery can exacerbate under-nutrition
by causing a systemic inflammatory response which in-
creases metabolic activity, elevates energy consumption, im-
pairs organ function and compromises immunity [37, 38].
Undernourished patients may be at risk of developing SSI
[15, 39], are at a greater risk of death and morbidity
[40, 41] and require more hospital resources than
normally nourished patients [42, 43]. Oral nutritional
supplements containing protein and/or arginine may
work to improve nutrition status and reduce the risk
of developing an SSI [44–48].
Findings reported from RCTs of oral nutritional sup-
plementation have been mixed across studies of both
single and multi-nutrient oral nutritional supplements.
For studies investigating the effect of single-nutrient oral
nutritional supplementation with a formula of either
protein, arginine or amino acids, a reduced rate of post-
operative infection complications was reported among
head and neck cancer surgery patients but the effect was
not statistically significant [49, 50]. Two further studies
were conducted to measure the effect of single-nutrient
oral nutritional supplements with no SSIs recorded
across the intervention control groups of two studies
[44, 45]. One study reported a statistically insignifi-
cant increase in SSIs following single-nutrient oral
nutritional supplementation and compared with the
control group [51].
Similarly, mixed findings have been reported from
RCTs of multi-nutrient oral nutritional supplements de-
fined as a formula of two or more nutrients comprising
energy sources and protein, arginine or amino acids. In
two studies, fewer SSIs were reported among individuals
who received multi-nutrient supplements across two
RCTs than those who received routine nutrition [46–48].
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In similar studies of multi-nutrient oral nutritional supple-
ments, no statistically significant difference in SSI rates
was demonstrated [52–54] whilst one study reported that
multi-nutrient oral nutritional supplements may increase
SSIs relative to routine nutrition [55].
To understand the available evidence and its quality, it
is important to search, analyse and report on the role of
oral nutritional supplements for preventing SSIs. This
systematic review may provide evidence to inform clin-
ical practice, as well as highlighting further areas for
investigation. Since SSIs have marked negative effects on
the person, health services and society across the globe
[56], it is important to identify effective interventions to
reduce their incidence. Principally, this review is neces-
sary to help find, appraise and summarise the current
evidence on the advantages and disadvantages of oral
nutritional supplements and present findings accord-
ingly. Thus, the objective of our planned systematic
review is to evaluate oral nutritional supplements on
preventing SSIs in adult surgical patients.
Methods/design
Inclusion and exclusion criteria
We will include published RCTs that include a state-
ment of peer review including theses, cluster RCTs and
N of 1 trials. We will include unpublished trials located
from conference abstracts and proceedings. We will only
include studies written in English as we do not have
access to scientific translation services. Studies using
quasi-randomisation will be excluded. We will include
studies of adults 18 or over of any gender who undergo
surgery, with or without abnormal body composition,
for example, any BMI, of any nutritional status or dis-
ease state. We will not exclude patients by surgical type
or by hospital setting. However, it is likely that most
studies will investigate patients undergoing major sur-
gery such as joint replacement, as oral nutritional sup-
plements are not typically prescribed for individuals
undergoing minor surgery such as cataract surgery.
We will include RCTs recruiting people described in
the primary report as receiving oral nutritional supple-
ments or no oral nutritional supplements or a placebo in
the hospital setting who undergo a surgical procedure.
Although we expect most studies will focus on oral nu-
tritional supplements as a treatment for under-nutrition,
we will include studies where oral nutritional supple-
ments are prescribed to supplement the diet of normally
nourished or obese patients. As the method of assessing
and defining nutritional status may vary, we will accept
definitions of normal nutrition and malnutrition as used
by the study authors.
The primary intervention of interest is oral nutritional sup-
plements containing either macronutrients, micronutrients
or a mixture of both. We will exclude studies investigating
supplements that do not contain an energy source (carbohy-
drates, fats, proteins). We will also exclude studies of single-
nutrient oral nutritional supplements or parenteral nutrition.
We will include RCTs in which the use of oral nutritional
supplements during the treatment period, either preopera-
tively or postoperatively, is the only interventional difference
between treatment groups. We anticipate that likely compar-
isons will include protein-enriched supplements compared
with immunonutrition supplements, such as supplements
enriched with arginine or glutamine, used during the care
pathway and added to standard practice, comparisons of
different types/brands of oral nutritional supplements or
comparisons of oral nutritional supplements with a placebo
or control such as no supplementation. The duration and
frequency of oral nutritional supplements compared with a
placebo or control will be reported.
We will exclude prebiotics, probiotics and synbiotics
as they are ingredients in food that are undigested in the
stomach but metabolised in the colon to promote bac-
terial growth or activity which may benefit health [57].
We will also exclude products which are administered
for purposes other than improving nutritional status. As
an example, medicinal herbs can be derived from edible
foods such as ginger, garlic, dandelion, lavender, fennel,
thyme, mint, liquorice, chamomile and St John’s Wort
and can be taken to achieve a pharmaceutical or phar-
macokinetic effect. All medicinal herbs, herbal therapies,
homoeopathic substances and zinc supplements will be
excluded from the review. We will only review interven-
tions where oral nutritional supplements have been
taken to supplement the oral diet as this is a typical ap-
proach for targeting improvements in the nutritional sta-
tus of surgical patients in the hospital setting as well as
the phenomena of interest in this review. Patients on
total parenteral nutrition (TPN) or receiving supple-
ments via a nasogastric tube will be excluded from the
review.
Outcome measures
We list primary and secondary outcomes below. If a
study is otherwise eligible (i.e. correct study design,
population and intervention/comparator) but does not
report a listed outcome, then we will contact the study
authors where possible to establish whether an outcome
of interest here was measured but not reported. Studies
will be excluded where it is clear that our primary out-
come was not measured.
We will report outcome measures at the latest time
point available, assumed to be length of follow-up if not
specified, and the time point specified in the methods as
being of primary interest, if this is different from the lat-
est time point available. For all outcomes, we will class
assessment of outcome measures in 2 categories:
Ralph et al. Systematic Reviews            (2020) 9:37 Page 3 of 10
 From up to 30 days after surgery for non-joint
replacement surgery
 From up to 90 days after surgery for joint-
replacement surgery
The primary outcome of this review is an evaluation of
oral nutrition supplements in SSIs. In the latest guide-
lines for prevention of SSIs [1], the CDC defines SSIs as
‘infections of the incision or organ or space that occur
after surgery’ (p785) and standardises the types of SSIs
into (a) superficial incisional, (b) deep incisional and (c)
organ space (CDC 2018b). Despite this, diagnosis of SSIs
varies between studies.
We will, therefore, accept the definition used by the
original authors to determine:
 The proportion of patients who developed any SSIs
before or after discharge from hospital within 30
days following surgery.
 For joint replacement surgery, we will limit
reporting to infections which occur within the first
90 days following surgery as per CDC diagnostic
guidelines which include this period in the SSI risk
period [58].
 We will report any reported incident of SSIs that
falls under these definitions as 1 event.
Secondary outcomes are:
 Changes to nutritional status. We will report
biological and immunological marker changes
compared with intervention and the control groups
including total protein (g/L), albumin (g/dl),
prealbumin (mg/dl) and total lymphocytes (103 in 1
μL/mm3 of blood). We will accept any validated
nutritional assessment tool measures taken at least
once prior to supplementation and at least once
after supplementation is ceased;
 Costs. Any cost effectiveness that relates costs to
benefits including but not limited to cost-utility or
incremental cost-effectiveness ratio;
 Mortality. We will include death up to 52 weeks
following surgery; and
 Health-related quality of life. We will include health-
related quality of life when reported where a
validated scale such as the SF-36 or EQ-5D was
used. We will not report ad hoc measures of quality
of life that are unlikely to be common to trials and
unvalidated.
Search strategy
We will search the following electronic databases to retrieve
reports of relevant randomised clinical trials: the Cochrane
Wounds Group Specialised Register (to present), the
Cochrane Central Register of Controlled Trials (CENTRAL)
(the Cochrane Library, latest issue), Ovid MEDLINE (1946
to present), Ovid MEDLINE (In-Process & Other Non-
Indexed Citations), Ovid Embase (1974 to present) and
EBSCO CINAHL Plus (1937 to present).
We will use the provisional search strategy in
Additional file 1 to search the Cochrane Central Register
of Controlled Trials (CENTRAL). We will combine the
Ovid MEDLINE search with the Cochrane Highly Sensi-
tive Search Strategy for identifying randomised trials in
MEDLINE: sensitivity- and precision-maximising version
(2008 revision) [59]. We will combine the Embase search
with the Ovid Embase filter developed by the UK
Cochrane Centre [59]. We will combine the CINAHL Plus
search with the trial filters developed by the Scottish Inter-
collegiate Guidelines Network [60]. There will be no re-
strictions with respect to date of publication or study
setting. We will also search the following clinical trial
registries: ClinicalTrials.gov, WHO International Clinical
Trials Registry Platform and EU Clinical Trials Register.
We will contact the corresponding authors for study
information and the manufacturers and distributors of
nutritional supplements for product information where
this is required. We will try to identify other potentially
eligible trials or ancillary publications by searching the
reference lists of retrieved included trials as well as rele-
vant systematic reviews, meta-analyses and health tech-
nology assessment reports.
Screening
Two review authors will independently assess the titles
and abstracts of the citations retrieved by the searches
for relevance. After this initial assessment, we will obtain
full text copies of all studies considered to be potentially
relevant. In teams of two, review authors will independ-
ently check the full papers for eligibility; disagreements
will be resolved by discussion and, where required, the
input of a third review author. Where required and pos-
sible, we will contact study authors where the eligibility
of a study is unclear. We will record all reasons for ex-
clusion of studies for which we had obtained full copies.
We will complete a PRISMA flowchart to summarise
this process and a PRISMA-P checklist is also appended
(see Additional file 2) [61]. Where studies have been re-
ported in multiple publications/reports, we will obtain
all publications. Whilst the study will be included only
once in the review, data will be extracted from all re-
ports to ensure maximal relevant data are obtained.
Extraction
We will extract and summarise details of the eligible
studies using a standardised data extraction sheet. Re-
view authors will extract data independently in pairs and
will resolve disagreements by discussion, drawing on a
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third review author where required. Where data are
missing from reports, we will attempt to contact the
study authors to obtain this information. Where a study
with more than two intervention arms is included, only
data from intervention and control groups that meet the
eligibility criteria will be extracted.
We will extract the following data where possible by
treatment group for the pre-specified interventions and
outcomes in this review. Outcome data will be collected
for relevant time points including:
 Country of origin
 Type of wound and surgery
 Unit of randomisation (per patient)—single wound
or multiple wounds on the same patient
 Unit of analysis
 Trial design such as parallel, cluster
 Care setting
 Number of participants randomised to each trial
arm
 Eligibility criteria and key baseline participant data
 Details of treatment regimen received by each group
 Commencement, end and duration of treatment
 Details of any co-interventions
 Primary and secondary outcome(s) (with definitions)
 Outcome data for primary and secondary outcomes
(by group)
 Duration of follow-up
 Number of withdrawals (by group)
 Blinding (both patient and professional)
 Publication status of study
 Source of funding for trial
 Patient demographics such as gender and age
Quality assessment
Two review authors will independently assess included
studies using the Cochrane tool for assessing risk of bias
[62]. This tool addresses six specific domains: sequence
generation, allocation concealment, blinding, incomplete
data, selective outcome reporting and other issues. In
this review we will record issues with unit of analysis,
for example, where a cluster trial has been undertaken
but analysed at the individual level in the study report.
We will assess blinding and completeness of outcome
data for each of the review outcomes separately. We
note that, since wound healing is a subjective outcome,
it can be at high risk of measurement bias when out-
come assessment is not blinded. We will present our as-
sessment of risk of bias using two ‘risk of bias’ summary
figures; one which is a summary of bias for each item
across all studies, and a second which shows a cross-
tabulation of each trial by all of the ‘risk of bias’ items.
We will class studies with an assessment of high risk of
bias for the randomisation sequence domain and/or the
allocation concealment domain and/or the blinded
outcome assessment domain (for specified outcome) as
being at overall high risk of bias (for specified outcome).
Where risk of bias judgement is made based on informa-
tion from correspondence with trial authors, this will be
noted in the risk of bias table. For trials using cluster
randomisation, we will also consider the risk of bias in
terms of recruitment bias, baseline imbalance, loss of
clusters, incorrect analysis and comparability with indi-
vidually randomised trials [63].
Analysis
For dichotomous outcomes, we will calculate the odds
ratio (OR) with 95% confidence intervals (CI). For
continuously distributed outcome data, we will use the
difference in means (MD) with 95% CIs, if all trials use
the same or similar assessment scale. If trials use differ-
ent assessment scales, we will use the standardised mean
difference (SMD) with 95% CIs. We will only consider
mean or median time to healing without survival ana-
lysis as a valid outcome if reports specify that all wounds
healed, meaning if the trial authors regarded time to
healing as a continuous measure as there is no censoring.
Time-to-event data such as time-to-complete wound heal-
ing will be reported as hazard ratios (HR) where possible
in accordance with the methods described in the
Cochrane Handbook [64]. If studies reporting time-to-
event data such as time to healing do not report a hazard
ratio, then, where feasible, we plan to estimate this using
other reported outcomes, such as the numbers of events,
through the application of available statistical methods
[65]. We will use the DerSimonian-Laird method to com-
bine OR as we anticipate using a random effects model
due to likely study heterogeneity [65].
Where studies randomise at the participant level and
measure outcomes at the wound level, such as wound
healing, we will treat the participant as the unit of ana-
lysis when the number of wounds assessed appears equal
to the number of participants (e.g. one wound per per-
son). There may be instances of clustered data where a
proportion of individually randomised trial participants
have outcome data collected and reported on multiple
wounds. Since not all participants will have multiple
wounds, this is not a cluster trial per se but rather a trial
that incorrectly includes a mixture of individual and
clustered data. Such trials will be noted and the issue
will be recorded in the risk of bias assessment. Data will
be extracted and presented but will not be the subject of
any further analyses.
We will only incorporate clearly conducted fully clus-
ter trials into meta-analyses if the trial has been analysed
correctly. Where a cluster trial has been conducted but
incorrectly analysed we will record this as part of the
‘risk of bias’ assessment. If possible, we will approximate
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the correct analyses based on Cochrane Handbook guid-
ance [63] using information on the number of clusters
(or groups) randomised to each intervention group or
the average (mean) size of each cluster; the outcome
data ignoring the cluster design for the total number of
individuals (for example, number or proportion of indi-
viduals with events, or means and standard deviations)
and an estimate of the intracluster (or intraclass) correl-
ation coefficient (ICC). Where multiple trial arms are
reported in a single trial, we will include only the rele-
vant arms. If two interventions or more interventions
are compared with the control and are eligible for the
same meta-analysis, we will pool the intervention arms
and compare that with the control. If the study data can-
not be analysed correctly, outcome data will be extracted
and presented but not analysed further.
It is common to have data missing from trial reports.
Excluding participants’ post-randomisation from the
analysis, or ignoring those participants who are lost to
follow up, compromises the randomisation and poten-
tially introduces bias into the trial. Where there are
missing data we think should be included in the ana-
lyses, we will contact the relevant study authors to re-
quest whether these data are available. We will adopt
the process detailed by Miller to evaluate the potential
bias of bivariate and multivariate comparisons of ‘stayers
and leavers’ [66]. For all secondary outcomes, we will
present available data from the study reports/study au-
thors and do not plan to impute missing data. Where
measures of variance are missing, we will calculate these
wherever possible. If calculation is not possible, we will
contact the study authors. Where these measures of
variance are not available, we will exclude the study
from any relevant meta-analyses that are conducted and
discuss the potential implications of its absence from a
meta-analysis.
Assessment of heterogeneity
Assessment of heterogeneity can be a complex, multi-
faceted process. Firstly, we will consider clinical and
methodological heterogeneity, that is, the degree to
which the included studies vary in terms of participant,
intervention, outcome and characteristics such as length
of follow-up. This assessment of clinical and methodo-
logical heterogeneity will be supplemented by informa-
tion regarding statistical heterogeneity, assessed using
the chi-squared test where a significance level of P <
0.10 will be considered to indicate statistically significant
heterogeneity, in conjunction with the I2 measure [67].
I2 examines the percentage of total variation across
RCTs that is due to heterogeneity rather than chance
[67]. In general, I2 values of 40%, or less, may not be
important [67]; and values of more than 75%, or more,
may indicate considerable heterogeneity [64]. We will
attempt to explore further where there is evidence of
high heterogeneity.
Assessment of bias
Reporting biases arise when the dissemination of re-
search findings is influenced by the nature and direction
of results. Publication bias is one of a number of possible
causes of small study effects, that is, a tendency for esti-
mates of the intervention effect to be more beneficial in
smaller RCTs. We will produce funnel plots as a visual
assessment of whether small study effects may be
present in a meta-analysis and as a means of estimating
the intervention effects from individual RCT against
some measure of each trial’s size or precision [68]. We
plan to present funnel plots for meta-analyses compris-
ing 10 RCTs or more.
Outcomes
Details of included studies will be combined in a narra-
tive review according to type of comparator, possibly by
location/type of wound and then by outcomes by time
period. Clinical and methodological heterogeneity will
be considered and pooling undertaken when studies
appear appropriately similar in terms of wound type,
intervention type, duration of follow-up and outcome
type.
We are unable to pre-specify the amount of clinical,
methodological and statistical heterogeneity in the in-
cluded studies but it might be extensive. Thus, we antici-
pate using a random effects approach for meta-analysis.
Conducting meta-analysis with a fixed effect model in
the presence of even minor heterogeneity may provide
overly narrow confidence intervals. We will only use a
fixed effect approach when clinical and methodological
heterogeneity are assessed to be minimal, and the
assumption that a single underlying treatment effect is
being estimated holds. Chi-squared and I2 will be used
to quantify heterogeneity but will not be used to guide
choice of model for meta-analysis. We will exercise cau-
tion when meta-analysed data are at risk of small study
effects because a random effects model may be unsuit-
able. In this case, or where there are other reasons to
question the selection of a fixed effect or random effects
model, we will assess the impact of the approach using
sensitivity analyses to compare results from alternate
models. We will report any evidence that suggests that
the use of a particular model might not be robust. We
may meta-analyse except when there is thought to be
extensive heterogeneity. We will attempt to explore
the causes behind this using meta-regression, if pos-
sible [69].
Data will be presented using forest plots where pos-
sible. For dichotomous outcomes, we will present the
summary estimate as an odds ratio (OR) with 95% CI.
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Where continuous outcomes are measured in the same
way across studies, we plan to present a pooled MD with
95% CI; we plan to pool [70] SMD estimates where studies
measure the same outcome using different methods. For
time-to-event data, we plan to plot and, if appropriate, to
pool, estimates of hazard ratios and 95% CIs as presented
in the study reports using the generic inverse variance
method. Where time to healing is analysed as a continu-
ous measure but it is not clear if all wounds healed, use of
the outcome in the study will be documented but data will
not be summarised or used in any meta-analysis.
We will present the main results of the review in ‘sum-
mary of findings’ tables; one table per comparison. The
tables will contain key information concerning the qual-
ity of the evidence, the magnitude of the effects of the
interventions examined and the sum of the available data
for the main outcomes [71]. The ‘summary of findings’
tables will also include an overall grading of the evidence
related to each of the main outcomes using the GRADE
(Grades of Recommendation, Assessment, Development
and Evaluation) approach [72]. The GRADE approach
defines the quality of a body of evidence as the extent to
which one can be confident that an estimate of effect or
association is close to the true effect. The quality of a
body of evidence involves consideration of within-trial
risk of bias (methodological quality), inconsistency be-
tween studies (heterogeneity), directness of evidence
(generalisability of population or outcomes), precision of
effect estimates and risk of publication bias [70]. We will
downgrade evidence using an approach adapted from
Dijkers (see Table 1) [73].
We plan to present the following outcomes in the
‘summary of findings’ tables: SSIs incidence, changes to
nutritional status, cost, mortality and health-related
quality of life. If sufficient data are available, we will
carry out subgroup analyses in order to determine po-
tentially important differences in the characteristics of
interventions or the effect of interventions on different
groups. We will assess potential heterogeneity. We will
consider the following subgroups:
1. Age such as < 18 years, ≥ 18 years and < 65 years
and ≥ 65 years
2. Gender
3. Type of surgery such as clean, clean/contaminated,
contaminated or dirty
4. Body composition according to CDC [74]
definitions of underweight, normal weight and
overweight such as BMI > 30 obese
5. Type of intervention such as protein-based or
arginine-based or both [75]
6. Degree of nutrition status such as classifications of
under-nutrition over nutrition or normal nutrition
as assessed by any nutrition assessment tool or as
defined by study authors [19–21]
7. Treatment regimen of nutrition supplement such as
time of initiation and period of dosing [76]
8. Low risk of bias versus unclear or high risk of bias
9. Biomarker levels (normal versus abnormal ranges)
Sensitivity analyses
Where possible, we plan to perform sensitivity analyses
to explore the impact or influence of key assumptions or
variations on effect estimates related to different nutri-
tional assessment tools used to define nutrition status.
Discussion
Since evaluating nutritional status, complications and inter-
ventions are complex; we anticipate there may be few
studies that appropriately address the research question.
Therefore, we will conduct preliminary searches to scope
the literature and systematically refine the search to ensure
inclusion of all relevant literature. Additionally, searching
and retrieving theses may prove to be complex. However,
we will use ProQuest Theses and Dissertation database as
well as the Gray Matters Application to minimise the
chance of missing potential studies. Given heterogeneity be-
tween interventions, outcomes and research designs is
likely, it may not be appropriate to meta-analyse the stud-
ies. Also, without large, cluster randomised controlled trials
distinguishing interventional effectiveness across surgical
demographics will be challenging. We will perform an ana-
lysis of evidence quality to counter this potential gap.
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